304 related articles for article (PubMed ID: 28466543)
1. Mutation patterns in genes encoding interferon signaling and antigen presentation: A pan-cancer survey with implications for the use of immune checkpoint inhibitors.
Budczies J; Bockmayr M; Klauschen F; Endris V; Fröhling S; Schirmacher P; Denkert C; Stenzinger A
Genes Chromosomes Cancer; 2017 Aug; 56(8):651-659. PubMed ID: 28466543
[TBL] [Abstract][Full Text] [Related]
2. Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma.
Zaretsky JM; Garcia-Diaz A; Shin DS; Escuin-Ordinas H; Hugo W; Hu-Lieskovan S; Torrejon DY; Abril-Rodriguez G; Sandoval S; Barthly L; Saco J; Homet Moreno B; Mezzadra R; Chmielowski B; Ruchalski K; Shintaku IP; Sanchez PJ; Puig-Saus C; Cherry G; Seja E; Kong X; Pang J; Berent-Maoz B; Comin-Anduix B; Graeber TG; Tumeh PC; Schumacher TN; Lo RS; Ribas A
N Engl J Med; 2016 Sep; 375(9):819-29. PubMed ID: 27433843
[TBL] [Abstract][Full Text] [Related]
3. Acquired IFNγ resistance impairs anti-tumor immunity and gives rise to T-cell-resistant melanoma lesions.
Sucker A; Zhao F; Pieper N; Heeke C; Maltaner R; Stadtler N; Real B; Bielefeld N; Howe S; Weide B; Gutzmer R; Utikal J; Loquai C; Gogas H; Klein-Hitpass L; Zeschnigk M; Westendorf AM; Trilling M; Horn S; Schilling B; Schadendorf D; Griewank KG; Paschen A
Nat Commun; 2017 May; 8():15440. PubMed ID: 28561041
[TBL] [Abstract][Full Text] [Related]
4. Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations.
Shin DS; Zaretsky JM; Escuin-Ordinas H; Garcia-Diaz A; Hu-Lieskovan S; Kalbasi A; Grasso CS; Hugo W; Sandoval S; Torrejon DY; Palaskas N; Rodriguez GA; Parisi G; Azhdam A; Chmielowski B; Cherry G; Seja E; Berent-Maoz B; Shintaku IP; Le DT; Pardoll DM; Diaz LA; Tumeh PC; Graeber TG; Lo RS; Comin-Anduix B; Ribas A
Cancer Discov; 2017 Feb; 7(2):188-201. PubMed ID: 27903500
[TBL] [Abstract][Full Text] [Related]
5. Loss of function JAK1 mutations occur at high frequency in cancers with microsatellite instability and are suggestive of immune evasion.
Albacker LA; Wu J; Smith P; Warmuth M; Stephens PJ; Zhu P; Yu L; Chmielecki J
PLoS One; 2017; 12(11):e0176181. PubMed ID: 29121062
[TBL] [Abstract][Full Text] [Related]
6. Overcoming Genetically Based Resistance Mechanisms to PD-1 Blockade.
Torrejon DY; Abril-Rodriguez G; Champhekar AS; Tsoi J; Campbell KM; Kalbasi A; Parisi G; Zaretsky JM; Garcia-Diaz A; Puig-Saus C; Cheung-Lau G; Wohlwender T; Krystofinski P; Vega-Crespo A; Lee CM; Mascaro P; Grasso CS; Berent-Maoz B; Comin-Anduix B; Hu-Lieskovan S; Ribas A
Cancer Discov; 2020 Aug; 10(8):1140-1157. PubMed ID: 32467343
[TBL] [Abstract][Full Text] [Related]
7. B2M and JAK1/2-mutated MSI-H Colorectal Carcinomas Can Benefit From Anti-PD-1 Therapy.
Zhang C; Li D; Xiao B; Zhou C; Jiang W; Tang J; Li Y; Zhang R; Han K; Hou Z; Zhang L; Sui Q; Liao L; Pan Z; Zhang X; Ding P
J Immunother; 2022 May; 45(4):187-193. PubMed ID: 35343934
[TBL] [Abstract][Full Text] [Related]
8. Tumor CDKN2A-Associated JAK2 Loss and Susceptibility to Immunotherapy Resistance.
Horn S; Leonardelli S; Sucker A; Schadendorf D; Griewank KG; Paschen A
J Natl Cancer Inst; 2018 Jun; 110(6):677-681. PubMed ID: 29917141
[TBL] [Abstract][Full Text] [Related]
9. Pan-cancer analysis of copy number changes in programmed death-ligand 1 (PD-L1, CD274) - associations with gene expression, mutational load, and survival.
Budczies J; Bockmayr M; Denkert C; Klauschen F; Gröschel S; Darb-Esfahani S; Pfarr N; Leichsenring J; Onozato ML; Lennerz JK; Dietel M; Fröhling S; Schirmacher P; Iafrate AJ; Weichert W; Stenzinger A
Genes Chromosomes Cancer; 2016 Aug; 55(8):626-39. PubMed ID: 27106868
[TBL] [Abstract][Full Text] [Related]
10. Chromosome 9p copy number gains involving PD-L1 are associated with a specific proliferation and immune-modulating gene expression program active across major cancer types.
Budczies J; Denkert C; Győrffy B; Schirmacher P; Stenzinger A
BMC Med Genomics; 2017 Dec; 10(1):74. PubMed ID: 29212506
[TBL] [Abstract][Full Text] [Related]
11. Successful immune checkpoint blockade in a patient with advanced stage microsatellite-unstable biliary tract cancer.
Czink E; Kloor M; Goeppert B; Fröhling S; Uhrig S; Weber TF; Meinel J; Sutter C; Weiss KH; Schirmacher P; Doeberitz MVK; Jäger D; Springfeld C
Cold Spring Harb Mol Case Stud; 2017 Sep; 3(5):. PubMed ID: 28619747
[TBL] [Abstract][Full Text] [Related]
12. Potential biomarker for checkpoint blockade immunotherapy and treatment strategy.
Dong ZY; Wu SP; Liao RQ; Huang SM; Wu YL
Tumour Biol; 2016 Apr; 37(4):4251-61. PubMed ID: 26779629
[TBL] [Abstract][Full Text] [Related]
13. Primary and acquired resistance to PD-1/PD-L1 blockade in cancer treatment.
Wang Q; Wu X
Int Immunopharmacol; 2017 May; 46():210-219. PubMed ID: 28324831
[TBL] [Abstract][Full Text] [Related]
14. Identification of essential genes for cancer immunotherapy.
Patel SJ; Sanjana NE; Kishton RJ; Eidizadeh A; Vodnala SK; Cam M; Gartner JJ; Jia L; Steinberg SM; Yamamoto TN; Merchant AS; Mehta GU; Chichura A; Shalem O; Tran E; Eil R; Sukumar M; Guijarro EP; Day CP; Robbins P; Feldman S; Merlino G; Zhang F; Restifo NP
Nature; 2017 Aug; 548(7669):537-542. PubMed ID: 28783722
[TBL] [Abstract][Full Text] [Related]
15. Genomic Analysis of Tumor Microenvironment Immune Types across 14 Solid Cancer Types: Immunotherapeutic Implications.
Chen YP; Zhang Y; Lv JW; Li YQ; Wang YQ; He QM; Yang XJ; Sun Y; Mao YP; Yun JP; Liu N; Ma J
Theranostics; 2017; 7(14):3585-3594. PubMed ID: 28912897
[TBL] [Abstract][Full Text] [Related]
16. Beyond melanoma: inhibiting the PD-1/PD-L1 pathway in solid tumors.
Gentzler R; Hall R; Kunk PR; Gaughan E; Dillon P; Slingluff CL; Rahma OE
Immunotherapy; 2016 May; 8(5):583-600. PubMed ID: 27140411
[TBL] [Abstract][Full Text] [Related]
17. PD-L1 Is Upregulated by Simultaneous Amplification of the PD-L1 and JAK2 Genes in Non-Small Cell Lung Cancer.
Ikeda S; Okamoto T; Okano S; Umemoto Y; Tagawa T; Morodomi Y; Kohno M; Shimamatsu S; Kitahara H; Suzuki Y; Fujishita T; Maehara Y
J Thorac Oncol; 2016 Jan; 11(1):62-71. PubMed ID: 26762740
[TBL] [Abstract][Full Text] [Related]
18. Resistance to checkpoint blockade therapy through inactivation of antigen presentation.
Sade-Feldman M; Jiao YJ; Chen JH; Rooney MS; Barzily-Rokni M; Eliane JP; Bjorgaard SL; Hammond MR; Vitzthum H; Blackmon SM; Frederick DT; Hazar-Rethinam M; Nadres BA; Van Seventer EE; Shukla SA; Yizhak K; Ray JP; Rosebrock D; Livitz D; Adalsteinsson V; Getz G; Duncan LM; Li B; Corcoran RB; Lawrence DP; Stemmer-Rachamimov A; Boland GM; Landau DA; Flaherty KT; Sullivan RJ; Hacohen N
Nat Commun; 2017 Oct; 8(1):1136. PubMed ID: 29070816
[TBL] [Abstract][Full Text] [Related]
19. Microsatellite instability derived JAK1 frameshift mutations are associated with tumor immune evasion in endometrioid endometrial cancer.
Stelloo E; Versluis MA; Nijman HW; de Bruyn M; Plat A; Osse EM; van Dijk RH; Nout RA; Creutzberg CL; de Bock GH; Smit VT; Bosse T; Hollema H
Oncotarget; 2016 Jun; 7(26):39885-39893. PubMed ID: 27213585
[TBL] [Abstract][Full Text] [Related]
20. Screening responsive or resistant biomarkers of immune checkpoint inhibitors based on online databases.
Xiang Z; Yu Y
Front Med; 2019 Feb; 13(1):24-31. PubMed ID: 30659409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
